Medical Innovations Pathways Takes the Stage at Granite School District’s Career Night
January 25, 2019
Yesterday, Utah’s life sciences companies participating in the Medical Innovations Pathways (MIP) program (www.medicalinnovationspathways.com), gathered at Granite School District as part of the district’s annual Career and Technical Education Open House. The Open House offers students a glimpse into a board range of industries. Representatives from BD, Edwards Lifesciences, Merit Medical, Nelson Laboratories, and Stryker set up company exhibits and made presentations during special medical device and laboratory testing breakout sessions.
“it was a great night,” said Jake Willis, Project Portfolio Manager with Nelson Laboratories. “We were able to talk directly to students and their parents, and help them understand what working in the life sciences industry is all about.”
The MIP program provides students with the opportunity to directly engage with leaders of Utah’s life sciences industry, and earn the Medical Innovations Certificate.
“We want students to enroll in MIP and come visit our facilities,” said Anthea Alono, Human Resources Director for Stryker. “Ultimately, we hope they come work for us and share in our passions for innovation and saving lives.”
The MIP program, now in its third year, is offered to high school seniors in Alpine, Canyons, Davis, Granite, Jordan, and Tooele school districts. In addition to completing required MIP coursework, students enrolled in the program will do company job shadows.
Recent News
- BD Launches Landmark Cell Analyzer Featuring Breakthrough Spectral and Real-Time Cell Imaging Technologies
- KyphoLift Debuts at ISMRM 2025: Transforming Patient Positioning for Safer, More Accurate Imaging
- Kelvyn Cullimore: An Unfair Penalty on Life-Saving Pills
- Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-Impermeable Endoprosthesis
- Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY® Arteriovenous Efficacy (WAVE) Trial
- Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology